Literature DB >> 29547022

Hypothesis: role for ammonia neutralization in the prevention and reversal of heart failure.

Oscar H L Bing1.   

Abstract

Ammonia plays a central role in the life and death of all living organisms and has been studied for over 100 yr. Ammonia is necessary for growth and development, but it is toxic in excess, and, as a result, differing methods of ammonia neutralization have evolved. After physiological and pathological stress to the heart, tissue ammonia levels rise. Local ammonia neutralization may be inadequate, and excess ammonia may exert its toxic effects. Phenylbutyrate (PBA), which is Federal Drug Administration approved for the treatment of elevated blood ammonia in urea cycle disorders, provides an accessory pathway for ammonia excretion. Recently, PBA has also been found to prevent specific cardiomyopathies. The central theme presents the hypothesis that stress to the myocardium from a variety of environmental sources causes injury, cell death, necrosis, and ammonia production. Ammonia, if not neutralized, exerts downstream toxic effects. Here, data are presented showing that neutralization with PBA alone and PBA combined with angiotensin-converting enzyme inhibition prevent and reverse pathophysiology associated with specific cardiomyopathies. NEW & NOTEWORTHY Ammonia produced after myocardial injury is hypothesized to be an upstream stress contributing to the pathophysiology of heart failure, effects that may be attenuated by a documented ammonia-reducing treatment. Reversal of heart failure can be achieved using an angiotensin-converting enzyme inhibitor combined with an ammonia-reducing treatment.

Entities:  

Keywords:  ammonia neutralization; cardiac hypertrophy and failure; phenylbutyrate

Mesh:

Substances:

Year:  2018        PMID: 29547022      PMCID: PMC6008145          DOI: 10.1152/ajpheart.00003.2018

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  39 in total

1.  Myocardial ammonia metabolism in patients with heart disease as revealed by coronary sinus catheterization study.

Authors:  E Chazov; V N Smirnov; A V Mazaev; G B Asafov; D U Gukowski; V I Krikov
Journal:  Circulation       Date:  1973-06       Impact factor: 29.690

2.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.

Authors:  K Swedberg; P Eneroth; J Kjekshus; L Wilhelmsen
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

3.  Attenuation of endoplasmic reticulum stress using the chemical chaperone 4-phenylbutyric acid prevents cardiac fibrosis induced by isoproterenol.

Authors:  Pedro Ayala; José Montenegro; Raúl Vivar; Alan Letelier; Pablo Aránguiz Urroz; Miguel Copaja; Deisy Pivet; Claudio Humeres; Rodrigo Troncoso; José Miguel Vicencio; Sergio Lavandero; Guillermo Díaz-Araya
Journal:  Exp Mol Pathol       Date:  2011-11-10       Impact factor: 3.362

4.  Transcriptional changes associated with recovery from heart failure in the SHR.

Authors:  Wesley W Brooks; Steven Shen; Chester H Conrad; Ronald H Goldstein; Lingyi Lynn Deng; Oscar H L Bing
Journal:  J Mol Cell Cardiol       Date:  2010-06-12       Impact factor: 5.000

5.  Myocardial protein metabolism following coronary occlusion.

Authors:  A Takahashi
Journal:  Jpn Circ J       Date:  1967-04

Review 6.  The nitric oxide pathway and oxidative stress in heart failure.

Authors:  Charles D Searles
Journal:  Congest Heart Fail       Date:  2002 May-Jun

7.  Protective effect of glutamic acid on cardiac function and metabolism during cardioplegia and reperfusion.

Authors:  O I Pisarenko; E S Solomatina; I M Studneva; V E Ivanov; V I Kapelko; V N Smirnov
Journal:  Basic Res Cardiol       Date:  1983 Sep-Oct       Impact factor: 17.165

8.  The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure.

Authors:  O H Bing; W W Brooks; K G Robinson; M T Slawsky; J A Hayes; S E Litwin; S Sen; C H Conrad
Journal:  J Mol Cell Cardiol       Date:  1995-01       Impact factor: 5.000

Review 9.  Histone deacetylase inhibition in the treatment of heart disease.

Authors:  Jeff M Berry; Dian J Cao; Beverly A Rothermel; Joseph A Hill
Journal:  Expert Opin Drug Saf       Date:  2008-01       Impact factor: 4.250

10.  Hormones in heart failure--regulation and counterregulation.

Authors:  A J Riegger
Journal:  Eur Heart J       Date:  1991-08       Impact factor: 29.983

View more
  3 in total

1.  The Efficacy of Lactulose for the Treatment of Hyperammonemic Encephalopathy Due to Severe Heart Failure.

Authors:  Koichi Narita; Eisuke Amiya; Nobutaka Kakuda; Hidehiro Kaneko; Masaru Hatano; Issei Komuro
Journal:  Diagnostics (Basel)       Date:  2020-01-27

2.  Relationship between the incidence of non-hepatic hyperammonemia and the prognosis of patients in the intensive care unit.

Authors:  Zhi-Peng Yao; Yue Li; Yang Liu; Hong-Liang Wang
Journal:  World J Gastroenterol       Date:  2020-12-07       Impact factor: 5.742

3.  A deep learning model for early risk prediction of heart failure with preserved ejection fraction by DNA methylation profiles combined with clinical features.

Authors:  Xuetong Zhao; Yang Sui; Xiuyan Ruan; Xinyue Wang; Kunlun He; Wei Dong; Hongzhu Qu; Xiangdong Fang
Journal:  Clin Epigenetics       Date:  2022-01-19       Impact factor: 6.551

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.